1. Key Insights
2. Report Introduction
3. Executive Summary of Breast Cancer
4. Key Events
5. SWOT Analysis
6. Breast Cancer Market Overview at a Glance in the 7MM
6.1. Total Market Size Distribution by class in Adjuvant/Neoadjuvant Setting in 2022
6.2. Total Market Size Distribution by class in Adjuvant/Neoadjuvant Setting in 2032
6.3. Total Market Size Distribution by class in First Line Setting in 2022
6.4. Total Market Size Distribution by class in First Line Setting in 2032
6.5. Total Market Size Distribution by class in Second Line and above Setting in 2022
6.6. Total Market Size Distribution by class in Second Line and above Setting in 2032
7. Disease Background and Overview
7.1. Introduction
7.2. Types of Breast Cancer
7.2.1. Subtypes of Breast Cancer
7.2.2. Molecular Subtypes of Breast Cancer
7.3. Estrogen Receptor (ER)-Positive Breast Cancer
7.3.1. Estrogen Receptor
7.3.2. Estrogen Receptor 1 Mutations
7.4. Metabolic Pathway of Breast Cancer
7.4.1. Role of Estrogen Receptor Alpha (ERa) in Regulating Breast Cancer Metabolism
7.5. Symptoms of Breast Cancer
7.6. Risk Factors of Breast Cancer
7.7. Diagnosis of Breast Cancer
7.8. Diagnostic Guidelines
8. Treatment of Breast Cancer
8.1. Treatment Algorithm of Breast Cancer
8.2. Treatment Guidelines for Breast Cancer
8.2.1. NCCN Clinical Practice Guidelines in Breast Cancer
9. Epidemiology and Patient Population of 7MM
9.1. Key Findings
9.2. Epidemiology Methodology
9.3. Assumptions and Rationale: 7MM
9.4. Total Incident cases of Breast Cancer in the 7MM
9.5. The United States
9.5.1. Total Incident cases of Breast Cancer in the United States
9.5.2. Incident cases of Breast Cancer Cases by Menopausal Status in the United States
9.5.3. Stage-Specific Incident cases of Breast Cancer in the United States
9.5.4. Subtype-specific Incident cases of Breast Cancer in the United States
9.5.5. Subtype-specific Incident cases of Breast Cancer by mutation in the United States
9.5.6. Treatment Eligible Pool for Early and Metastatic Breast Cancer in the United States
9.6. EU4 and the UK
9.6.1. Total Incident cases of Breast Cancer in EU4 and the UK
9.6.2. Incident cases of Breast Cancer Cases by Menopausal Status in EU4 and the UK
9.6.3. Stage-Specific Incident cases of Breast Cancer in EU4 and the UK
9.6.4. Subtype-specific Incident cases of Breast Cancer in EU4 and the UK
9.6.5. Subtype-specific Incident cases of Breast Cancer by mutation in EU4 and the UK
9.6.6. Treatment Eligible Pool for Early and Metastatic Breast Cancer in EU4 and the UK
9.7. Japan
9.7.1. Total Incident cases of Breast Cancer in Japan
9.7.2. Incident cases of Breast Cancer Cases by Menopausal Status in Japan
9.7.3. Stage-Specific Incident cases of Breast Cancer in Japan
9.7.4. Subtype-specific Incident cases of Breast Cancer in Japan
9.7.5. Subtype-specific Incident cases of Breast Cancer by mutation in Japan
9.7.6. Treatment Eligible Pool for Early and Metastatic Breast Cancer in Japan
10. Patient Journey
11. Marketed Products
11.1. Key-cross Competition
11.2. KISQALI (ribociclib; LEE011): Novartis
11.2.1. Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activity
11.2.4. Clinical Development
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. PIQRAY (alpelisib; BYL719): Novartis
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Clinical Development
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. VERZENIO (abemaciclib): Eli Lilly
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Clinical Development
11.4.4. Safety and efficacy
11.4.5. Product Profile
11.5. IBRANCE (palbociclib): Pfizer
11.5.1. Product Description
11.5.2. Regulatory Milestones
11.5.3. Clinical Development
11.5.4. Safety and efficacy
11.5.5. Product Profile
11.6. LYNPARZA (olaparib): AstraZeneca
11.6.1. Product Description
11.6.2. Regulatory Milestones
11.6.3. Clinical Development
11.6.4. Safety and efficacy
11.6.5. Product Profile
11.7. AFINITOR (everolimus): Novartis
11.7.1. Product Description
11.7.2. Regulatory Milestones
11.7.3. Safety and efficacy
11.7.4. Product Profile
11.8. FASLODEX (fulvestrant) Injection: AstraZeneca
11.8.1. Product Description
11.8.2. Regulatory Milestones
11.8.3. Safety and efficacy
11.8.4. Product Profile
List to be continued in the report
12. Emerging Therapies
12.1. Key Cross Competition
12.2. Enobosarm: Veru
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.3. Amcenestrant (SAR439859): Sanofi
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.4. Giredestrant (RG6171, GDC-9545): Roche
12.4.1. Product Description
12.4.2. Clinical Development
12.4.3. Safety and Efficacy
12.5. Camizestrant (AZD9833): AstraZeneca
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Safety and Efficacy
12.6. LY3484356/Imlunestrant: Eli Lilly
12.6.1. Product Description
12.6.2. Clinical Development
12.6.3. Safety and Efficacy
12.7. Lerociclib: EQRx
12.7.1. Product Description
12.7.2. Other Developmental Activities
12.7.3. Clinical Development
12.7.4. Safety and Efficacy
12.8. TRODELVY (sacituzumab govitecan): Gilead
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.9. Capivasertib: AstraZeneca
12.9.1. Product Description
12.9.2. Clinical Development
12.9.3. Safety and Efficacy
12.10. Lasofoxifene: Sermonix Pharmaceuticals
12.10.1. Product Description
12.10.2. Other Developmental Activities
12.10.3. Clinical Development
12.10.4. Safety and Efficacy
12.11. SFX-01: Evgen Pharma
12.11.1. Product Description
12.11.2. Other Developmental Activities
12.11.3. Clinical Development
12.11.4. Safety and Efficacy
12.12. SM-88: Tyme
12.12.1. Product Description
12.12.2. Clinical Development
12.12.3. Safety and Efficacy
12.13. Inavolisib: Roche/ Genentech
12.13.1. Product Description
12.13.2. Clinical Development
12.14. Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo
12.14.1. Product Description
12.14.2. Other Development Activities
12.14.3. Clinical Development
List to be continued in the report
13. Breast Cancer: 7MM Market Analysis
13.1. Key Finding
13.2. Total Market Size of Breast Cancer in the 7MM
13.3. Market Methodology
13.4. Conjoint Analysis
13.5. Key Market Forecast Assumptions
13.6. Market Outlook
13.7. United States Market Size
13.7.1. Total Market Size of Breast Cancer in the United States
13.7.2. Market Size of Breast Cancer in Adjuvant/Neoadjuvant Setting in the United States
13.7.3. Market Size of Breast Cancer in First Line Setting in the United States
13.7.4. Market Size of Breast Cancer in Second Line Setting and Above in the United States
13.8. EU4 and the UK Market Size
13.8.1. Total Market Size of Breast Cancer in EU4 and the UK Market Size
13.8.2. Market Size of Breast Cancer in Adjuvant/Neoadjuvant Setting in EU4 and the UK
13.8.3. Market Size of Breast Cancer in First Line Setting in EU4 and the UK
13.8.4. Market Size of Breast Cancer in Second Line Setting and Above in EU4 and the UK
13.9. Japan Market Size
13.9.1. Total Market Size of Breast Cancer in Japan
13.9.2. Market Size of Breast Cancer in Adjuvant/Neoadjuvant Setting in Japan
13.9.3. Market Size of Breast Cancer in First Line Setting in Japan
13.9.4. Market Size of Breast Cancer in Second Line Setting and Above in Japan
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
16.1. Bibliography
16.2. Report Methodology
17. Sciinov Insight Capabilities
18. Disclaimer
